Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxathridine first-in-human single ascending dose and sleep proof-of-concept study
NL-OMON38728Phase 1Active, not recruiting
- Sponsor
- Bioprojet
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of roxatidine in sleep disorder (6 arms), sponsored by Bioprojet. Primary endpoints: Safety and tolerability and Polysomnography. Started Oct 2014; status: active, not recruiting.
02
Drugs
roxatidine
03
Conditions
sleep disorder
Beyond the preview
Go deeper on NL-OMON38728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38728.